SOM Biotech announces that its product development partnership with Vall d’Hebron Research Institute (VHIR) successfully completed the Phase IIa clinical trial of SOM0226, repositioned drug for TTR Amyloidosis. Final study results are expected in December 2015.

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.